In liver fibrosis rat model, TFLC (200 mg/kg) was able to ameliorate liver injury by reducing serum contents of ALT, AST, hyaluronic acid, laminin, procollagen III N-terminal peptide, procollagenase IV and hydroxyproline, and suppressing the expressions of α-smooth muscle actin, collagen I, transforming growth factor-β1 (TGF-β1) and transforming growth factor β receptor 1 (TGF-βR1) (Huang et al. Here, TGFB1 is linked to Hepatic fibrosis.